First-line therapy and mitochondrial damage: Different nucleosides, different findings

HIV Clinical Trials

Volumn 4, Issue 1, 2003, Pages 11-19

  Blanco, Francisco ^a   García Benayas, Teresa ^a   de la Cruz, Juan José ^b   González Lahoz, Juan ^a   Soriano, Vincent ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

HAART; HIV; Hyperlactatemia; Lactate; Lactic acidosis; Mitochondrial toxicity; Nucleoside analogues

Indexed keywords

ABACAVIR; ALKALINE PHOSPHATASE; AMYLASE; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; GAMMA GLUTAMYLTRANSFERASE; LACTATE DEHYDROGENASE; LACTIC ACID; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ZALCITABINE;

ADULT; AMYLASE BLOOD LEVEL; ARTICLE; BODY BUILD; BODY WEIGHT DISORDER; CELL DAMAGE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG TOLERABILITY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; INCIDENCE; LACTATE BLOOD LEVEL; LACTATE DEHYDROGENASE BLOOD LEVEL; LACTIC ACIDOSIS; LIPOATROPHY; LIPODYSTROPHY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MITOCHONDRION; MULTIVARIATE ANALYSIS; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; L-LACTATE DEHYDROGENASE; LACTIC ACID; MALE; MIDDLE AGED; MITOCHONDRIA;

EID: 0242500956     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/HF1J-3P6K-1K9H-AGPY     Document Type: Article

References (42)

1. Carr A, Cooper D. Adverse effects of antiretroviral therapy. Lancet. 2000;356:1423-1430.
2. Blanco F, Carr A. Lipodystrophy syndrome: diagnostic, clinic and therapeutic aspects. AIDS Rev. 2001;3:98-105.
3. Brinkmann K, ter Hofstede H, Burger D, Smeitink J, Koopmans P. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as a common pathway. AIDS. 1998;12:1735-1744.
4. White A. Mitochondrial toxicity and HIV therapy. Sex Transmit Inf. 2001;77:158-173.
5. Sanders R. Another surprise from the mitochondrial genome. N Engl J Med. 2002;347:609-611.
6. Moyle G. Hyperlactatemia and lactic acidosis during antiretroviral therapy: causes, management and possible etiologies. AIDS Rev. 2001;3:150-156.
7. Kakuda T. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther. 2000;22:685-708.
8. John M, Moore C, James I, et al. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS. 2001;15:717-723.
9. Boubaker K, Flepp M, Sudre P, et al. Hyperlactatemia and antiretroviral therapy: the Swiss Cohort Study. Clin Infect Dis. 2001;33:1931-1937.
10. Moyle GJ, Datta D, Mandalia S, Morlese J, Asboe D, Gazzard B. Hyperlactatemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. AIDS. 2002;16:1341-1349.
11. Gopinath R, Hutcheon M, Cheemer-Dhadli S, Halperin M. Chronic lactic acidosis in a patient with AIDS and mitochondrial myopathy: biochemical studies. J Am Soc Nephrol. 1992;3:1212-1219.
12. Chattha G, Arieff A, Cummings C, Tierney L Jr. Lactic acidosis complicating the acquired immunodeficiency syndrome. Ann Intern Med. 1993;118:37-39.
13. Brinkman K, Hofstede H. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: lactic acidosis, risk factors and therapeutic options. AIDS Rev. 1999;1:141-148.
14. Falcó V, Rodríguez D, Ribera E, et al. Severe nucleoside-associated lactic acidosis in HIV-infected patients: report of 12 cases and review of the literature. Clin Infect Dis. 2002;34:838-846.
15. Barbaro G, Lorenzo G, Asti A, et al. Hepatocellular mitochondrial alterations in patients with chronic hepatitis C: ultrastructural and biochemical findings. Am J Gastroenterol. 1999;94:2198-2205.
16. Saint-Marc T, Partisani M, Pizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS. 1999;13:1659-1667.
17. Carr A, Miller J, Law M, Cooper D. A syndrome of lipoatrophy, lactic acidemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS. 2000;14:F25-F32.
18. Mallal S, John M, Moore C, James I, McKinnon E. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS. 2000;14:1309-1316.
19. Gómez M, Miró O, Pedrol E, et al. Mitochondrial involvement in antiretroviral therapy-related lipodystrophy. AIDS. 2001;15:1643-1651.
20. Shikuma C, Ningjie H, Milne C, et al. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS. 2001;15:1801-1809.
21. Walker U, Bickel M, Volksbeck S, et al. Evidence of nucleoside analogue reverse transcriptase inhibitor-associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients. J Acquir Immune Defic Syndr. 2002;29:117-121.
22. Carpenter C, Cooper D, Fischl M, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA. 2000;283:381-390.
23. Yeni P, Hammer S, Carpenter C, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA. 2002;288:222-235.
24. Joly V, Descamps D, Yeni P. NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens. AIDS Rev. 2002;4:128-139.
25. D'Arminio-Monforte A, Cozzi-Lepri A, Rezza G, et al. Insights into the reasons for discontinuation of the first HAART regimen in a cohort of antiretroviral-naive patients. AIDS. 2000;14:499-507.
26. Boffito M, Marietti G, Audagnotto S, Raiter R, Di Perri G. Lactacidemia in asymptomatic HIV-infected subjects receiving nucleoside reverse transcriptase inhibitors. Clin Infect Dis. 2002;34:558-559.
27. Lonergan J, Behling C, Pfander H, Hassanein T, Mathews W. Hyperlactatemia and hepatic abnormalities in ten HIV-infected patients receiving nucleoside combination regimens. Clin Infect Dis. 2000;31:162-166.
28. Gérard Y, Maulin L, Yazdanpanah Y, et al. Symptomatic hyperlactatemia: an emerging complication of antiretroviral therapy. AIDS. 2000;14:2723-2730.
29. Brinkmann K. Management of hyperlactatemia: no need for routine lactate measurements. AIDS. 2001;15:795-797.
30. Carr A, Workman C, Smith D, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy. A randomized trial. JAMA. 2002;288:207-215.
31. García-Benayas T, Blanco F, Soriano V, González-Lahoz J. Replacing stavudine by abacavir reduces lactate levels and may improve lipoatrophy. AIDS. In press.
32. Boyle B, Basuk P, Emancipator K. Prevalence, etiology and long-term follow-up of asymptomatic, HIV-infected patients with hyperamylasemia. In: Program and abstracts of the XIV International AIDS Conference; July 7-12, 2002; Barcelona, Spain. Abstract MoPeB3164.
33. Moore R, Keruly J, Chaisson R. Incidence of pancreatitis in HIV-infected patients on nucleoside RTIs. In: Program and abstracts of the Eighth Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago, USA. Abstract 620.
34. Rotig A, Cormier V, Blanche S, et al. Pearson's marrow-pancreas syndrome. A multisystem mitochondrial disorder in infancy. J Clin Invest. 1990;86:1601-1608.
35. Allaouchiche B, Duflo F, Cotte L, et al. Acute pancreatitis with severe lactic acidosis in an HIV-infected patient on didanosine therapy. J Antimicrob Chemother. 1999;44:137-138.
36. Coghlan M, Somadossi JP, Jhala N, Many W, Saag M, Johnson V. Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with HIV infection: a report of 12 cases. Clin Infect Dis. 2001;33:1914-1921.
37. Bissuel F, Brunell F, Habersetzer F, et al. Fulminant hepatitis with severe lactate acidosis in HIV-1-infected patients on didanosine therapy. J Intern Med. 1994;235:367-372.
38. Tebas P, Powderly W, Claxton S, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS. 2000;14:F63-F67.
39. Mondy K, Tebas P. Bone abnormalities in HIV-infected patients on HAART. AIDS Rev. 2001;3:82-88.
40. Carr A, Miller J, Eisman J, Cooper D. Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy. AIDS. 2001;15:703-709.
41. Heath K, Hogg R, Singer J, et al. Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based cohort. J Acquir Immune Defic Syndr. 2002;30:440-447.
42. Martínez E, Mocroft A, García-Viejo M, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet. 2001;357:592-598.